Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00343239
Status:
COMPLETED
Last Update Posted:
2014-11-04
First Post:
2006-06-21
Brief Title:
Docetaxel in Locally Advanced Gastric Adenocarcinoma
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Docetaxel Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma Phase II Clinical Study
Status:
COMPLETED
Status Verified Date:
2014-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NEOTAX
Brief Summary:
Study objectives
To determine Ro resection rate of Docetaxel cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma
To determine Ro resection rate of Docetaxel cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None